May 8, 2008
Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter
Volcano Corporation (Nasdaq: VOLC) announced today the first human procedure using the Volcano OCT Imaging catheter. The procedure was performed by Dr. Patrick Serruys at the Thoraxcenter, in Rotterdam, Netherlands. Volcano OCT will complement its existing line of IVUS imaging catheters and pressure guidewires used for coronary imaging and lesion assessment. (Read more...)

May 7, 2008
Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today reported results for the first quarter of fiscal 2008. (Read more...)

May 5, 2008
Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
SATURN is a 104-week, parallel-group, multicentre, double-blind, Phase IIIb intravascular ultrasound (IVUS) imaging study of approximately 1,300 patients at 170 centres This study by AstraZeneca is designed to measure the impact of CRESTOR™ (rosuvastatin) 40 mg and atorvastatin (Lipitor®) 80 mg on the progression of atherosclerosis in high risk patients. SATURN will compare the effects of these two statins on the ability to decrease progression or induce regression of atherosclerosis, the main cause of cardiovascular disease, following two years of treatment in patients with coronary artery disease. (Read more...)

April 29, 2008
Volcano Corporation Schedules First Quarter Conference Call, Webcast
Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement(FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will report its operating results for the first quarter of fiscal 2008 on Wednesday, May 7. (Read more...)

March 31, 2008
Volcano Corporation Announces North America Resale Agreement with Royal Philips Electronics
Volcano Corporation, leading manufacturer of intravascular ultrasound (IVUS), announced today that it has entered into a non-exclusive, resale agreement covering North America with Royal Philips Electronics. Under this agreement, Philips will resell Volcano-branded s5i IVUS systems and accessories alongside of the Philips Allura Xper FD X-ray systems. (Read more...)

March 28, 2008
Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
Volcano Corporation, a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today the U.S. and European launch of the s5-Revo and s5-FFR (fractional flow reserve) options for the s5i integrated Imaging platform. (Read more...)

March 27, 2008
Intravascular Ultrasound (IVUS) Events at American College of Cardiology Annual Meeting
Intravascular ultrasound (IVUS) is scheduled to be part of 29 separate sessions at this weekend's annual meeting of cardiologists in Chicago. In addition, IVUS will be used by interventionalists who will be performing 14 live procedures, to be broadcast to the Convention Center at McCormick Place from Lenox Hill Hospital in New York, and other medical centers in California, London, Germany, Japan and Australia. (Read more...)

March 12, 2008
Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
Volcano Corporation (Nasdaq: VOLC), a leading provider of intravascular ultrasound (IVUS) and functional measurement (FM) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, will be participating in the Cowen and Company 28th Annual Health Care Conference on Monday, March 17. The presentation by president and CEO, Scott Huennekens, will begin at 3:15 p.m., Eastern Daylight Time (12:15 Pacific Daylight Time). (Read more...)

February 12, 2008
Volcano Reports 35% Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46%
"This growth in our IVUS business occurred despite a sluggish global PCI market. We believe the ease of use and integration provided by our s5 family of consoles, along with a growing volume of data demonstrating the value of IVUS in stenting procedures, is driving our increased market presence in the IVUS arena," he added. "We are encouraged by what appear to be recent favorable trends in stenting procedures and believe this will further the growth of our IVUS offerings," he continued. (Read more...)

February 7, 2008
Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
These two new product offerings now enable rotational IVUS and FFR to operate on the same integrated Volcano s5 Imaging System as Volcano's previous line of phased array IVUS catheters and functionality. For the first time, physicians can choose among three powerful diagnostic tools -- all on the same integrated IVUS platform. (Read more...)

December 10, 2007
Volcano Announces Agreement to Acquire CardioSpectra
Volcano Corporatio, a provider of intravascular ultrasound (IVUS) and functional measurement (FM) products designed to enhance the diagnosis and treatment of vascular and structural heart disease, said today that it has reached a definitive agreement to acquire CardioSpectra, Inc., a privately-held company developing innovative Optical Coherence Tomography (OCT) technology. CardioSpectra's unique OCT imaging system is expected to complement Volcano's existing product offerings and will further enhance Volcano's position as an imaging technology leader in the field of interventional medicine. (Read more...)

November 8, 2007
Volcano Reports Record Third Quarter Revenues
Volcano Corporation, a leading provider of intravascular ultrasound (IVUS) and functional measurement (FM) products, today reported record revenues of $31.5 million, a 13 percent increase over revenues of $27.8 million in the third quarter a year ago. (Read more...)

November 8, 2007
Cordis Europe Partnering With Volcano Europe to Provide Access to Intravascular Imaging (IVUS) for Use in Drug-Eluting Stent Procedures
One of the major drug-eluting stent makers seems to agree with the idea that intravascular ultrasound (IVUS) guidance is critical for the proper placement of their devices. This move is a significant one for Volcano, which has long been trying to educate the interventional cardiology community about IVUS. (Read more...)

October 22, 2007
Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
Volcano Corporation, a leading manufacturer of intravascular ultrasound (IVUS) and functional measurement (FM) technology, announced today activities planned for the 2007 Transcatheter Cardiovascular Therapeutics (TCT) conference that will take place from October 20th to October 25th in Washington D.C. (Read more...)

October 22, 2007
Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome
3,000 patients will be studied as part of a multi-center IVUS sub-study, part of the Cardiovascular Research Foundation's ADAPT-DES Study to quantify the causes and cures of thrombosis in drug-eluting stents. (Read more...)

September 4, 2007
Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
Volcano Corporation, a provider of intravascular ultrasound (IVUS) and functional measurement (FM) products designed to enhance the diagnosis and treatment of vascular and structural heart diseases, said today that it will be participating in the Bear Stearns 2007 Healthcare Conference on Tuesday, September 11. (Read more...)

July 24, 2007
Volcano Corporation Announces Japan Approval of the s5i Integrated IVUS Platform
Volcano Corporation today announced approval of the s5i Integrated IVUS System by necessary regulatory authorities in Japan, granting entry into the Japanese market. Volcano expects to launch the s5i into Japan, which represents the largest Intravascular Ultrasound (IVUS) market worldwide, during the current quarter. (Read more...)

May 30, 2007
Most Heart Stents Are Placed Imperfectly, Increasing Risk of Heart Attack or Reclosure
Results of a new study show that stent placement involves a "geographic miss" two-thirds of the time, resulting in a three-fold increased risk of heart attack and a two-fold increase in reintervention. The article includes interviews with Dr. Marco Costa of the University of Florida College of Medicine in Jacksonville, chief investigator for the S.T.L.L.R. study, and Dr. Antonio Colombo of Columbus and San Raffaele Hospitals in Milan, Italy (Read more...)

May 7, 2007
Volcano Corporation Reports 49 Percent Increase in Revenues; IVUS Disposable Sales Increase 33 Percent
(source: Volcano Corporation)
Volcano Corporation, a leading provider of intravascular ultrasound (IVUS) and functional measurement (FM) products designed to enhance the diagnosis and treatment of vascular and structural heart diseases, today reported that revenues in the first quarter of 2007 increased 49 percent over revenues in the first quarter a year ago. (Read more...)

April 25, 2007
Volcano Corporation Schedules First Quarter Conference Call, Webcast
(source: Volcano Corporation)
The company will hold a conference call to discuss its financial results and operating activities to all interested parties at 2 p.m., Pacific Daylight Time (5 p.m. Eastern Daylight Time), Monday, May 7, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer. (Read more...)

April 18, 2007
COURAGE, SPIRIT Data May Support Role of Advanced Imaging and Diagnosis With IVUS and FFR
(source: Volcano Corporation)
The results of recent studies presented at this year's American College of Cardiology may support the role played by intravascular ultrasound (IVUS) and fraction flow reserve (FFR) in diagnosing the need for stenting more accurately than standard angiography and, when the use of a stent is indicated, aiding in the accuracy of stent placement. (Read more...)

April 4, 2007
Volcano Corp. Reports Use of Intravascular Ultrasound (IVUS) Increasing as Physicians Refocus on Stent Technique
While use in the United States of DES has decreased from 89% to an estimated 70% over the past year, driven by concerns over stent thrombosis causing heart attacks, and confidence in Bare Metal Stent (BMS) safety, for the same period, Volcano has seen an increase of 25% in IVUS revenue, demonstrating more reliance on detailed imaging to guide optimal DES and BMS placement. (Read more...)

April 3, 2007
Volcano Corporation and ev3 Inc. Announce Joint Marketing and Distribution Agreement
Under the terms of the agreement, Volcano will have the opportunity to sell ev3's SpiderFX Embolic Protection Device in conjunction with their Intravascular Ultrasound (IVUS) and Functional Measurement (FM) devices for use in saphenous vein grafts (SVG's) in the U.S. (Read more...)

February 13, 2007
Volcano Corporation and Cordis Endovascular Japan Announces Distribution Agreement for IVUS Indications
(source: Volcano Corporation)
Volcano Corporation today announced the signing of a distribution agreement with Johnson & Johnson K.K., Medical Company.The agreement appoints Cordis Endovascular Systems Japan as a distributor of IVUS products for use in peripheral and endovascular procedures in Japan.

November 27, 2006
Intravascular Ultrasound (IVUS) Imaging Technology May Help Lower Rates of Late Stent Thrombosis
While there are a number of causes of late stent thrombosis that have been identified, one of the factors most associated is poor apposition (incomplete expansion or suboptimal positioning) of the drug-eluting stent. A recent presentation by Dr. William Wijns of Aalst, Belgium at last month's TCT meeting showed that in 77% of the late stent thrombosis cases (clotting one year after implantation) the stent showed incomplete apposition (mal-apposition was seen in only 12% of cases where there was no stent thrombosis). (Read more...)

November 13, 2006
Volcano Announces Clinical Review of Key Presentations From TCT 2006
(source: Volcano Corporation)
The whole field of intravascular ultrasound (IVUS) is gaining in importance as problems are surfacing about drug-eluting stents. The value of IVUS

October 20, 2006
Volcano Corporation and MediGuide Ltd. Announce Collaboration for Advanced Imaging and Navigation Technology
(source: Volcano Corporation)
The companies initially plan to develop Guided IVUS (GIVUS), a product which will integrate MediGuide's Medical Positioning System (MPS) with Volcano's intravascular ultrasound (IVUS) system. This combination of technologies will expand the two dimensional aspect of the existing IVUS image into a three dimensional image that is designed to provide more useful clinical information, allow for easier interpretation of the image by interventional cardiologists and improve the clinical utility of the image.

October 11, 2006
Volcano Announces First Permanent Installations of the Integrated s5i IVUS Imaging System
(source: Volcano Corporation)
The company today announced the first permanent installations of the s5i IVUS (intravascular ultrasound) imaging system in both the U.S. and Europe. The s5i is Volcano's first IVUS system that can be integrated into any new or existing cath lab configuration. Through a series of customizable components, Volcano can now tailor an integrated IVUS solution to the unique user and workflow needs for any vendor's cath lab type or configuration.

August 24, 2006
GE Healthcare and Volcano Corporation Announce FDA Clearance of Fully-Integrated Intravascular Ultrasound Imaging on the Innova Platform
(source: GE Healthcare and Volcano Corporation)
The FDA has given clearance to a new integrated state-of-the-art intravascular ultrasound (IVUS) platform with an all-digital X-ray cath lab imaging system. (Read more...)

August 30, 2006
Abbott Announces Completion of Enrollment in Groundbreaking Vulnerable Plaque Study
Utilizing the Volcano Therapeutics' intravascular ultrasound imaging system, the PROSPECT study, headed by Dr. Gregg Stone of Columbia University Medical Center in New York, will attempt to more clearly define who is at risk for a heart attack by looking at vulnerable plaque, not just plaque "build-up". (Read more...)